Extracellular matrix-derived peptides and myocardial repair.
Repairing cardiac tissue remains one of the most challenging goals in tissue engineering. Here, we discuss ways whereby we sought to treat myocardial infarctions using extracellular-matrix derived peptides. Using an ischemia/reperfusion myocardial infarction rodent model, we targeted these extracellular matrix-derived peptides to the myocardial infarct site and were able to induce angiogenesis and alter the negative remodeling seen after an acute myocardial infarction. Our results indicate a potentially new strategy for repairing damaged tissue.
Cardiovascular Research Institute, University of California-San Francisco, CA, USA.
Shirley S
SS
Mihardja
Jiashing
J
Yu
Randall J
RJ
Lee
D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000906:Antibodies / Q000378:metabolism; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000737:chemistry; D016326:Extracellular Matrix Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D018796:Immunoconjugates / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D015427:Reperfusion Injury / Q000139:chemically induced / Q000188:drug therapy*; D023822:Tissue Engineering / Q000379:methods; D020257:Ventricular Remodeling / Q000187:drug effects
D043925:Angiogenesis Inducing Agents; D000906:Antibodies; D016326:Extracellular Matrix Proteins; D018796:Immunoconjugates; D010455:Peptides